Artelo BiosciencesARTL
ARTL
About: Artelo Biosciences Inc is a United States-based development-stage biopharmaceutical company. It is engaged in development of therapeutics that target lipid signaling pathways, including the endocannabinoid system, a family of receptors and neurotransmitters that form a biochemical communication network in body. It is focused on discovering, licensing, developing, and commercializing treatments that control endocannabinoid systems. The company pursues technologies and programs that offer proprietary approaches to cannabinoid-based therapies, also those derived from the cannabis plant and synthetic cannabinoids, as well as new chemical entities and compounds. The firm's flagship program is designed to be a patent-protected cannabinoid drug combination treatment for a rare and orphan disease.
Employees: 6
0
Funds holding %
of 6,809 funds
0
Analysts bullish %
of 3 analysts
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
0.1% less ownership
Funds ownership: 0.8% [Q2] → 0.7% (-0.1%) [Q3]
17% less funds holding
Funds holding: 6 [Q2] → 5 (-1) [Q3]
28% less capital invested
Capital invested by funds: $35.7K [Q2] → $25.6K (-$10.1K) [Q3]
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 1
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 3
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$5
428%
upside
Avg. target
$5.67
498%
upside
High target
$6
533%
upside
3 analyst ratings
3 positive
100%
0 neutral
0%
0 negative
0%
D. Boral Capital Jason Kolbert 25% 1-year accuracy 38 / 150 met price target | 533%upside $6 | Buy Maintained | 9 Dec 2024 |
HC Wainwright & Co. Vernon Bernardino 32% 1-year accuracy 19 / 59 met price target | 428%upside $5 | Buy Reiterated | 9 Dec 2024 |
EF Hutton Jason Kolbert 25% 1-year accuracy 38 / 150 met price target | 533%upside $6 | Buy Initiated | 1 Oct 2024 |
Financial journalist opinion
Neutral
GlobeNewsWire
1 week ago
Artelo Biosciences Announces Presentation of Phase 1 Data with ART27.13 in Cancer-Related Anorexia
Phase 1 data from the CAReS trial showed an attractive safety profile and promising activity from daily ART27.13 administration with two-thirds of participants having stabilized or reversed weight loss at one month of treatment Phase 1 data from the CAReS trial showed an attractive safety profile and promising activity from daily ART27.13 administration with two-thirds of participants having stabilized or reversed weight loss at one month of treatment
Neutral
GlobeNewsWire
1 month ago
Artelo Biosciences to Present Key Data on Three Development Programs at the 7th Cannabinoid Drug Development Summit
SOLANA BEACH, Calif., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatological and neurological conditions, today announced that Professor Saoirse O'Sullivan, Vice President of Translational Sciences at Artelo, will be presenting at the 7th Cannabinoid-Derived Drug Development Summit. The event will take place November 18-20, 2024, at the Wyndham Beacon Hill Hotel in Boston, MA.
Neutral
GlobeNewsWire
1 month ago
Artelo Biosciences Announces Promising New Data on Novel Non-Opioid Treatment Approach for Osteoarthritis Pain at the 13th Annual Musculoskeletal Repair and Regeneration Symposium
ART26.12, the Company's Lead Clinical Fatty Acid Binding Protein 5 Inhibitor, Continues to Show Positive Preclinical Results in Multiple Pain Studies ART26.12, the Company's Lead Clinical Fatty Acid Binding Protein 5 Inhibitor, Continues to Show Positive Preclinical Results in Multiple Pain Studies
Neutral
GlobeNewsWire
1 month ago
Artelo Biosciences Announces Acceptance of ART26.12 into the National Institutes of Health's “Preclinical Screening Platform for Pain” Program
SOLANA BEACH, Calif., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatologic and neurological conditions, today announced that ART26.12, the Company's lead clinical FABP inhibitor, has been accepted into the NIH Helping to End Addiction Long Term (HEAL) Initiative's Preclinical Screening Platform for Pain (PSPP).
Neutral
GlobeNewsWire
2 months ago
Artelo Biosciences CEO to Participate in Fireside Chat at the Maxim Group Virtual Healthcare Summit on October 16th
SOLANA BEACH, Calif., Oct. 09, 2024 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatologic and neurological conditions today announced that it will be participating in the Maxim Group 2024 Virtual Healthcare Summit being held October 15-17, 2024.
Neutral
GlobeNewsWire
3 months ago
Artelo Biosciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference
SOLANA BEACH, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatologic and neurological conditions today announced that Gregory D. Gorgas, CEO of Artelo Biosciences, will be participating in the H.C. Wainwright 26th Annual Global Investment Conference being held September 9-11, 2024 at the Lotte New York Palace Hotel in New York City.
Neutral
GlobeNewsWire
4 months ago
Artelo Biosciences Reports Second Quarter 2024 Financial Results and Provides Business Update
SOLANA BEACH, Calif., Aug. 13, 2024 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatologic and neurological conditions, today reported its financial and operating results for the three months ended June 30, 2024 and provided a business update.
Neutral
GlobeNewsWire
5 months ago
Artelo Biosciences Receives FDA Clearance of its IND Application for ART26.12, a Selective Fatty Acid Binding Protein 5 Inhibitor
ART26.12 seeks to address a critical need in painful neuropathies, including chemotherapy-induced peripheral neuropathy for which there is no FDA-approved treatment
Neutral
GlobeNewsWire
5 months ago
Artelo Biosciences Presents Comparative Data from Key Preclinical Studies on ART12.11 at the 34th Annual International Cannabinoid Research Society Symposium
Multiple studies confirm ART12.11's superior advantages as a product candidate for the treatment of anxiety related disorders Multiple studies confirm ART12.11's superior advantages as a product candidate for the treatment of anxiety related disorders
Neutral
GlobeNewsWire
6 months ago
Artelo Biosciences Presents Important New Data on ART26.12 at the 57th Annual Scientific Meeting of the British Pain Society
ART26.12 shows efficacy in breast cancer-induced bone pain and diabetic neuropathy ART26.12 shows efficacy in breast cancer-induced bone pain and diabetic neuropathy
Charts implemented using Lightweight Charts™